
    
      4300 type 2 diabetes (T2D) patients on monotherapy or drug naive. Randomization 1:1,
      metformin, dosing according to treatment guidelines or SGLT2 inhibitor, dapagliflozin 10 mg
      od.

      844 events estimated for study completion (90% power to detect hazard ratio (HR) <0.8 for
      dapagliflozin vs metformin ) Endpoint collection during study duration (about 4 years) from
      national health care registers: Patient, Prescribed drugs, Cause of death and Population
      registers; National diabetes register (NDR) Primary analysis according to insulin tolerance
      test (ITT)
    
  